At a Glance
Intravenous fluorouracil is FDA‑approved in adults for the treatment of various solid tumors, including cancers of the colon and rectum, breast, stomach, pancreas, and head and neck, usually as part of combination chemotherapy.
Generic/Biosimilar name: Fluorouracil.
Active ingredient: Fluorouracil.
Administration route: Intravenous.
Typical intravenous fluorouracil dosing in adults ranges from about 200–600 mg/m²/day in regimens given as intermittent bolus injections or continuous infusions, with exact dose and schedule varying by cancer type and combination protocol.
How It Works
- Fluorouracil is a type of chemotherapy that looks like a natural building block of DNA and RNA, so cancer cells take it up when they divide.
- Inside the cell, it blocks an enzyme needed to make DNA (thymidylate synthase) and also gets built into RNA, which stops cells from growing and making proteins.
- Because cancer cells divide faster than most normal cells, they are more likely to be damaged and destroyed by the drug.
Treatment and Efficacy
Approved indications: Intravenous fluorouracil is approved, usually in combination with other drugs, for treatment of adenocarcinoma of the colon and rectum (including adjuvant and metastatic settings), breast cancer, gastric and pancreatic cancers, and head and neck cancers.
Off‑label uses and evidence: It is sometimes used off‑label in other gastrointestinal and hepatobiliary malignancies or as part of radiosensitizing regimens; these uses are supported mainly by clinical trials and oncology guidelines but may not be specifically listed on the U.S. label.
Efficacy expectations and timing: Tumor response is typically assessed after several cycles (often 2–3 months) using scans, lab tests, and symptom changes; many patients achieve disease control (tumor shrinkage or stabilization), though cure is mainly expected in earlier‑stage disease when used as adjuvant therapy.
Comparison to similar drugs: Fluorouracil is a backbone drug in many regimens and has long‑term survival data in colorectal and other cancers; oral prodrugs such as capecitabine can offer similar efficacy in some settings with greater convenience but different side‑effect profiles.
Dosage and Administration
Typical dosing and administration: Intravenous fluorouracil doses in adults often range from about 200–600 mg/m² per day, given as short bolus injections, prolonged infusions over 22–24 hours, or continuous infusions over several days, as part of regimens such as FOLFOX, FOLFIRI, or chemoradiation protocols; dosing is calculated from body surface area and adjusted for the specific cancer, prior treatment, and tolerance.
Administration details: The drug is given through a vein, often via a central venous catheter or port; when used in combination regimens, it is administered in a set order with other chemotherapy and supportive medications under supervision by oncology staff.
Special instructions: Doses may be reduced, delayed, or stopped if blood counts are low, if there is significant diarrhea, mucositis, or other toxicity, or if organ function worsens; continuous‑infusion regimens may use an ambulatory pump that should be handled exactly as instructed by the care team.
Missed doses: Fluorouracil schedules are tightly planned; if a clinic visit or infusion is missed, patients should contact their oncology team promptly for instructions rather than trying to “make up” a dose themselves.
Overdose: Suspected overdose or severe early toxicity requires urgent medical evaluation; treatment may include intensive supportive care and, in some cases, use of the antidote uridine triacetate, which is most effective when started as soon as possible after overdose or onset of severe symptoms.
Safety and Side Effects
Common side effects: Frequent reactions include nausea, vomiting, diarrhea, mouth sores, poor appetite, fatigue, and low blood counts (especially low white cells), which usually develop days to weeks after dosing and can range from mild to severe depending on dose and combination therapy.
Serious or rare adverse effects: Seek urgent medical attention for fever or signs of infection, severe or bloody diarrhea, uncontrolled vomiting, severe mouth sores, chest pain or shortness of breath (possible heart effects), confusion or neurologic changes, or signs of severe allergic reaction.
Warnings and precautions: Use in pregnancy can harm the unborn baby and is generally avoided; effective contraception is recommended during treatment and for a period after the last dose, and breastfeeding is not recommended while receiving fluorouracil.
Organ function and special risks: Dose adjustments or extra monitoring may be needed in people with liver dysfunction, poor nutritional status, or prior intensive chemotherapy or radiation; patients with dihydropyrimidine dehydrogenase (DPD) deficiency are at high risk for life‑threatening toxicity and may require avoidance or major dose reduction.
Relative safety profile: Compared with many newer agents, fluorouracil’s side‑effect pattern is well characterized from decades of use, but it still carries substantial risks of myelosuppression, gastrointestinal toxicity, and, rarely, cardiotoxicity, so careful dosing and monitoring are essential.
Reporting side effects and safety updates: Patients and clinicians in the United States can report suspected adverse reactions to the FDA MedWatch program and check FDA and manufacturer communications for ongoing safety updates.
Interactions and Precautions
Drug interactions: Fluorouracil can interact with several medicines, notably increasing toxicity when combined with leucovorin (used intentionally to enhance effect) and potentially interacting with warfarin (increasing bleeding risk), phenytoin, certain antivirals, and other chemotherapy agents.
Other products, foods, and alcohol: Alcohol can worsen liver irritation, dehydration, and mouth sores and is best limited or avoided; there are no major food interactions, but maintaining good hydration and nutrition is important, and patients should discuss all over‑the‑counter medicines, vitamins, and herbal supplements with their oncology team.
Precautions and conditions that increase risk: Pre‑existing DPD deficiency, significant bone‑marrow suppression, active infections, uncontrolled heart disease, or severe liver dysfunction can make fluorouracil use unsafe or require substantial dose modification and close oversight.
Monitoring needs: Regular blood tests are required to monitor blood counts, liver and kidney function, and, when relevant, clotting parameters if used with anticoagulants; clinicians also monitor for gastrointestinal toxicity, mucositis, neurologic changes, and cardiac symptoms during and after treatment cycles.
Diagnostic and imaging procedures: Fluorouracil generally does not interfere with standard imaging tests, but recent chemotherapy should be shared with radiology and procedural teams, especially before surgery or invasive procedures where low blood counts or bleeding risk are concerns.
Common Questions and Answers
Q: What types of cancer are usually treated with intravenous fluorouracil?
A: It is most commonly used, usually with other drugs, to treat colorectal, breast, gastric, pancreatic, and head and neck cancers, and sometimes other gastrointestinal tumors.
Q: How long will I need to stay on fluorouracil treatment?
A: The number of cycles depends on your diagnosis and treatment goal; adjuvant therapy may last several months, while treatment for advanced disease often continues as long as it is helping and side effects remain manageable.
Q: What side effects should make me call my doctor right away?
A: Call immediately for fever, signs of infection, severe or bloody diarrhea, uncontrolled vomiting, chest pain, trouble breathing, severe mouth sores, confusion, or any sudden, severe worsening of how you feel.
Q: Can I work and do normal activities during fluorouracil chemotherapy?
A: Many people can continue some usual activities, but fatigue, clinic visits, and side effects may limit what you can do; your care team can help you plan work, rest, and infection‑prevention strategies.
Q: Is there an oral alternative to intravenous fluorouracil?
A: In some situations, oral capecitabine or other regimens can be used instead, offering similar benefits for certain cancers, but the choice depends on your cancer type, other health conditions, and preferences, and should be decided with your oncologist.
Better Treatment, Lower Cost – No Catch.
Find safer, more effective medications with fewer side effects – often for less money. It’s fast, free, and personalized. Learn More →
Disposal Guidance
For patients, fluorouracil is usually prepared and stored by the clinic, infusion center, or pharmacy, and is kept refrigerated or at controlled room temperature according to the product label, protected from light.
If you are sent home with an infusion pump or any leftover supplies, keep them out of reach of children and pets, do not open or reuse any containers or tubing, and return pumps and unused medication to the clinic or pharmacy as instructed.
Used needles, tubing, and other contaminated items should go into puncture‑resistant sharps or chemotherapy waste containers provided by your care team, not into household trash or recycling.